  A work recently published experimentally demonstrates an increase in the
radiobiological efficacy of clinical proton beams when a tumour is treated in
the presence of a concentration of 11B. The paper, for the first time,
demonstrates the potential role of the p+11B to 3{\alpha} (for brevity, p-B)
reaction in the biological enhancement of proton therapy effectiveness. The
work reports robust experimental data in terms of clonogenic cell survival and
chromosomal aberrations and unambiguously shows the presence of an enhancement
when cells were exposed to a clinical proton beam subject to treatment with
sodium boroncaptate (BSH). Moreover, the greater occurrence of complex-type
chromosomal exchanges points to the effect as due radiation of a LET (Linear
Energy Transfer) greater than that of protons alone, possibly the alpha
particles generated by the reaction. At the same time, we emphasized that
analytical calculations, performed on the basis of the well-known total
production cross section data, are not able to explain the effect in a
macroscopic way, i.e. solely in terms of a trivial increase in the total dose
released in the cells by the alpha-particles. In this paper, thanks to
simulations and analytical calculations, we will discuss the theoretically
expected alpha particle yield and the corresponding LET and RBE (Relative
Biological Effectiveness) increase related to the 11B presence. We conclude
that a mere calculation based on the classical concepts of integral Dose, and
average LET and RBE cannot be used to justify the observed radiobiological
phenomena. We, therefore, suggest that micro- and nano-dosimetric aspects must
be taken into account.
